Reuters logo
BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab
April 18, 2017 / 8:15 PM / in 6 months

BRIEF-Ultragenyx, Kyowa Hakko Kirin, Kyowa Kirin announce positive 24-week data from adult phase 3 study of burosumab

April 18 (Reuters) - Ultragenyx Pharmaceutical Inc

* Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of Burosumab (KRN23) in X-linked hypophosphatemia

* Ultragenyx Pharmaceutical Inc - study met primary endpoint of serum phosphorus response and key secondary endpoint of stiffness improvement

* Ultragenyx Pharmaceutical Inc - patients treated with burosumab demonstrated a statistically significant improvement in serum phosphorus levels

* Ultragenyx Pharmaceutical Inc - there have been no deaths in study

* Ultragenyx - Of 134 patients enrolled, 1 patient in burosumab arm discontinued treatment during 24-week double-blind treatment period due to consent withdrawal Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below